bpc-157 intra-articular knee injection human study A-H. Gross presentation of injury severity. A poor course in all Therapeutic Peptides in Orthopaedics:... :

Kannt A, Pfenninger A, Teichert L, Tnjes A, Dietrich A, Schn MR, Klting N, Blher M. Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance. Diabetologia. 2015 Apr;58(4):799-808. doi: 10.1007/s00125-014-3490-7. Epub 2015 Jan 18. PMID: 25596852; PMCID: PMC4351435

Some protocols increase to 200 mcg of each after assessing initial response

8,262 This may be a contributing factor in the relationship between high homocysteine levels and psycho-emotional conditions such as depression, as well as the higher risk of depression seen in carriers of the MTHFR gene variant associated with impaired folate metabolism

Here are signs that your dose may need adjustment: Signs the dose is too high: Persistent nausea beyond 3 weeks at current dose level Regular vomiting (more than once per week) Severe constipation not responding to hydration and fiber Food aversion (inability to eat adequate nutrition) Rapid weight loss exceeding 1.5% of body weight per week Signs the dose is too low: No noticeable change in appetite or satiety Minimal or no reduction in food intake Weight has plateaued for 4 or more weeks No gastrointestinal effects whatsoever (some mild effects indicate the drug is working) Signs you are at the right dose: Moderate appetite suppression (eating less without feeling starved) Steady, sustainable weight changes Mild or no side effects Improved satiety (feeling satisfied with smaller portions) Stable energy levels throughout the day Finding the right dose is a process

Originally identified for its anti-ulcer effects in the stomach, BPC-157 showed a broad range of protective capabilities in lab tests

Low intake has been linked with a higher risk of depression among women [2]